Want to see SPRB full AI Analyst Report?
Spruce Biosciences (SPRB) Ratios
Spruce Biosciences Ratios
SPRB's free cash flow for Q2 2026 was $-22.25M. For the 2026 fiscal year, SPRB's free cash flow was decreased by $-135.00K and operating cash flow was $-22.12M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.17 | 2.90 | 4.18 | 6.72 | 10.36 |
| Quick Ratio | 5.17 | 2.90 | 4.18 | 6.72 | 10.36 |
| Cash Ratio | 4.85 | 2.54 | 3.94 | 1.97 | 4.82 |
| Solvency Ratio | -3.71 | -3.23 | -1.74 | -2.69 | -2.79 |
| Operating Cash Flow Ratio | -3.30 | -3.67 | -1.36 | -3.35 | -4.04 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -34.50 | -20.51 | -25.70 | 0.00 |
| Net Current Asset Value | $ 41.61M | $ 27.82M | $ 74.75M | $ 66.45M | $ 76.78M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.06 | 0.04 | 0.07 | 0.05 |
| Debt-to-Equity Ratio | 0.02 | 0.10 | 0.06 | 0.09 | 0.06 |
| Debt-to-Capital Ratio | 0.02 | 0.09 | 0.06 | 0.08 | 0.06 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.02 | 0.05 | 0.04 |
| Financial Leverage Ratio | 1.25 | 1.57 | 1.36 | 1.25 | 1.14 |
| Debt Service Coverage Ratio | -431.72 | -27.31 | -22.50 | -22.37 | -121.39 |
| Interest Coverage Ratio | -405.70 | -182.90 | -107.65 | -112.58 | -121.93 |
| Debt to Market Cap | 0.00 | 0.10 | 0.03 | 0.10 | 0.02 |
| Interest Debt Per Share | 1.08 | 5.73 | 10.17 | 11.01 | 11.32 |
| Net Debt to EBITDA | 1.24 | 0.68 | 1.94 | 0.40 | 0.86 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | -1073.69% | -470.18% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | -1072.76% | -469.48% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | -1143.37% | -515.34% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | -1079.94% | -474.96% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | -1079.94% | -474.96% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | -1079.94% | -474.96% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 106.72% | 94.45% | 92.16% | 97.67% | 100.54% |
| Return on Assets (ROA) | -73.49% | -117.31% | -46.10% | -53.92% | -33.44% |
| Return on Equity (ROE) | -91.65% | -184.02% | -62.63% | -67.43% | -37.97% |
| Return on Capital Employed (ROCE) | -85.04% | -187.40% | -65.42% | -64.59% | -35.77% |
| Return on Invested Capital (ROIC) | -84.42% | -176.20% | -63.91% | -63.08% | -35.66% |
| Return on Tangible Assets | -73.49% | -117.31% | -46.10% | -53.92% | -33.44% |
| Earnings Yield | -58.35% | -313.86% | -43.56% | -91.75% | -20.82% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 5.26 | 8.54 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.11 | 0.10 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.09 | 0.14 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -43.47 | -104.32 | -66.47 | -68.14 | -59.07 |
| Free Cash Flow Per Share | -43.47 | -104.32 | -66.48 | -68.16 | -59.22 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -4753.57 | -5210.38 | -385.77 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -4753.57 | -5210.38 | -385.77 |
| Operating Cash Flow Coverage Ratio | -45.28 | -20.24 | -7.22 | -6.60 | -5.49 |
| Operating Cash Flow to Sales Ratio | 0.00 | -11.40 | -3.30 | 0.00 | 0.00 |
| Free Cash Flow Yield | -49.91% | -331.19% | -30.25% | -82.83% | -17.70% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.71 | -0.33 | -2.30 | -1.09 | -4.80 |
| Price-to-Sales (P/S) Ratio | 0.00 | 3.44 | 10.90 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.57 | 0.59 | 1.44 | 0.73 | 1.82 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.00 | -0.30 | -3.31 | -1.21 | -5.65 |
| Price-to-Operating Cash Flow Ratio | -2.00 | -0.30 | -3.31 | -1.21 | -5.66 |
| Price-to-Earnings Growth (PEG) Ratio | 0.04 | -0.08 | -0.08 | -0.20 | -0.12 |
| Enterprise Value Multiple | -0.48 | 0.36 | -0.39 | -0.70 | -3.99 |
| Enterprise Value | 18.61M | -19.09M | 18.28M | 32.16M | 166.96M |
| EV to EBITDA | -0.48 | 0.36 | -0.39 | -0.70 | -3.99 |
| EV to Sales | 0.00 | -3.89 | 1.81 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.56 | 0.34 | -0.55 | -0.77 | -4.64 |
| EV to Operating Cash Flow | -0.56 | 0.34 | -0.55 | -0.77 | -4.65 |
| Tangible Book Value Per Share | 55.46 | 53.73 | 152.82 | 111.96 | 183.36 |
| Shareholders’ Equity Per Share | 55.46 | 53.73 | 152.82 | 111.96 | 183.36 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 9.15 | 20.15 | 0.00 | 0.00 |
| Net Income Per Share | -50.83 | -98.87 | -95.72 | -75.49 | -69.63 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.01 | 1.01 | 1.01 | 1.01 |
| Research & Development to Revenue | 0.00 | 9.45 | 4.90 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 2.98 | 1.25 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 1.09 | 0.46 | 0.00 | 0.00 |
| Income Quality | 0.86 | 1.06 | 0.69 | 0.90 | 0.85 |
Currency in USD